The American Action Forum yesterday released new analysis of recent calls for the federal government to negotiate drug prices in Medicare. AAF health care expert Robert Book contends that direct government interference in drug pricing could have a range of negative consequences, from discouraging further research to driving up prices. These consequences stand in stark contrast to the advantages of the market-based pricing mechanism used in Medicare Part D, which has allowed government costs to come in significantly under budget without government intervention.

Click here to read the analysis.

Click here to read Book’s related op-ed in Forbes.